Award Background

The Best Podium Research Presentation Award was established in 1998 to recognize the scientific merit exhibited on the podium presentation.

Category:

GENERAL (up to 3 awards each conference)

NEW INVESTIGATOR (up to 3 awards each conference)

STUDENT (up to 3 awards each conference)


 

Criteria:

Background provides appropriate perspective / context for the subject

Objectives / research questions are clearly stated

Research design / methods / modeling is appropriate and transparent {scores on this will determine winners in case of ties}

Data sources and/or sampling procedures are clear and appropriate

Research objectives are met/addressed

Factual information is kept separate from interpretations or implications

Abstract is presented in an unbiased manner

Clarity of presentation


 

Selection Process:

All contributed podium presentations are considered for the awards.


 

Selection of Judges:

3 weeks prior to conference, select preconference registrants are invited to participate to judge podium presentations

Judges are asked to select their field of interest


 

Judging Process:

Judges are assigned presentations according to their field of interest

Each judge evaluates 1 presentation

All presentations are judged equally regardless of categories. Judges do not know whether the presentation is student, new investigator, or general

Judges' scores are compiled per category and analyzed

Committee chair(s) determine the recipients of the awards (up to 3 in each category)


 

Nature of the Award:

A certificate with an inscription stating the award name, name of the author, and title of the presentation shall be sent to the award recipient after the conference when the conditions of acceptance are met.


 

Conditions of Acceptance:

To receive the award, the awardee must submit to the podium slide presentation / poster presentation for which the award is given for publication at the website, along with author permission. Failure to submit presentation slides and permission within the designated timeframe will result in forfeiture of award.


 

Award Announcements:

Official announcement of the recipients will occur after the conference via Value & Outcomes Spotlight, eBulletin, the website, and an email to conference attendees.


 


Best Research Podium Presentation Award Recipients

 

ISPOR Conference Award Winners

ISPOR 2018

Best General Podium Presentations

Ashley Jaksa

Health Technology Assessment Agencies Consideration of Real-World Evidence [HT4]
Context Matters, New York, NY, USA

Erin Arthurs

Dolutegravir and Rilpivirine to Treat Virologically Suppressed Adults Living With HIV-1: A Canadian Cost-Utility Analysis [AV3]
GSK, Mississauga, ON, Canada

Louis P. Garrison

“It’s Tough to Make Predictions, Especially About the Future”: Comparing Life Expectancy Predictions Based on Period Versus Cohort Life Tables [VA3]
University of Washington, Seattle, WA, USA

Best Student Podium Research Presentations

Xue Han

Secondary Prevention Using Cholesterol-Lowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis [CV2]
University of Southern California, Los Angeles, CA, USA

Xiaohan Hu

Trends in the Economic Value of Newly Approved Cancer Therapies in the US [VA2]
University of Southern California, Los Angeles, CA, USA

Francesco Saverio Mennin

Economic Consequences of Anti-HCV Antiviral Treatment Investment From the NHS Perspective [VA4]
Faculty of Economics, Centre for Economic and International Studies-Economic Evaluation and Health Technology Assessment, University of Rome Tor Vergata, Rome, Italy

Best New Investigator Podium Research Presentations

Nicolae Done

Comparative Effectiveness of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation [CV3]
Veterans Health Administration, Boston, MA, USA

JA Voelker

Annual Change in Controlled Substance Opioid Prescribing and Concomitant Medications From an Urban Academic Emergency Department From 2011–2016 [HU1]
Jefferson College of Population Health at Thomas Jefferson University, Philadelphia, PA, USA

Christopher G Fawsitt

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Duration in Genotype 1 Non-Cirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus [AV2]
University of Bristol, Bristol, UK

ISPOR 2017 (22nd Annual)

Best General Podium Presentations

Kristina Secnik Boye

PP4 - VALIDATION OF A QUESTIONNAIRE TO ASSESS PATIENT PERCEPTIONS OF INJECTION DEVICES FOR TYPE 2 DIABETES
Boye KS2, Matza LS1, Stewart KD1, Paczkowski R2, Currie BM1, Yu R1, Coyne KS1
1Evidera, Bethesda, MD, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

Stephen S. Johnston

MD4 - COMPARISON OF ECONOMIC AND CLINICAL OUTCOMES BETWEEN THE DERMABOND® PRINEO® SKIN CLOSURE SYSTEM AND SKIN STAPLES IN PATIENTS UNDERGOING KNEE REPLACEMENT IN REAL WORLD CLINICAL PRACTICE
Johnston SS1, Sutton N2
1Johnson & Johnson Co., New Brunswick, NJ, USA, 2Ethicon Inc., Somerville, NJ, USA

Best Student Podium Research Presentations

Rahul Garg

CN2 - IMPACT OF DIFFUSE LARGE B-CELL LYMPHOMA ON VISITS TO DIFFERENT PROVIDER SPECIALTIES AMONG ELDERLY MEDICARE BENEFICIARIES: CHALLENGES FOR CARE COORDINATION
Garg R1, Sambamoorthi U2, Tan X2, Basu SK3, Haggerty T1, Kelly K1
1West Virginia University, Morgantown, WV, USA, 2West Virginia University, School of Pharmacy, Morgantown, WV, USA, 3University of Louisville, Louisville, KY, USA

Weihsuan Lo-Ciganic

TP4 - GEOGRAPHIC VARIATION OF INAPPROPRIATE PRESCRIPTION OPIOID USE AMONG DISABLED MEDICARE BENEFICIARIES
Zhou L1, Kwoh CK1, Gellad WF2, Donohue JM3, Roubal A4, Hines L5, Malone D1, Bhattacharjee S1, Lee JK1, Lindermann J6, Bell M1, Westra J1, Lo-Ciganic W1
1University of Arizona, Tucson, AZ, USA, 2Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, 3University of Pittsburgh, Pittsburgh, PA, USA, 4Robert Wood Johnson Foundation, Princeton, NJ, USA, 6Pharmacy Quality Alliance, Springfield, VA, USA, 6ESRI Inc., Broomfield, CO, USA

Yingnan Zhao

DB2 - RACIAL DISPARITY IN ACCESS TO NEWER CLASS ANTI-DIABETICS AMONG ADULT PATIENTS WITH DIABETES IN THE U.S.
Zhao Yo, Cooley K
Xavier University of Louisiana, New Orleans, LA, USA

Best New Investigator Podium Research Presentations

Lindsey E Falk

MD1 - COST EFFECTIVENESS OF THE LEFT ATRIAL APPENDAGE CLOSURE DEVICE COMPARED WITH ORAL ANTICOAGULANTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
Falk LE1, Wijeysundera HC2, Sikich N1, Dhalla I1, Ng V1
1Health Quality Ontario, Toronto, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Chia-Te Liao

CV2 - ECONOMIC EVALUATION OF ALTERNATIVE ANTICOAGULANT DRUGS FOR THE PREVENTION OF STROKE AMONG 65-YEAR OLD ATRIAL FIBRILLATION PATIENTS IN TAIWAN
Liao C, Lee M
Chimei medical center, Tainan, Taiwan

ISPOR 2016 (21st Annual)

Best General Podium Presentations

ME2 - MEDICARE PART D COST SHARING AND SPECIALTY DRUG INITIATION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS

Doshi JA1, Li P1, Huo H1, Pettit AR1, Kumar R1, Huntington SF2, Weiss BM31University of Pennsylvania, Philadelphia, PA, USA, 2Yale University, New Haven, CT, USA, 3Hospital of the University of Pennsylvania, Philadelphia, PA, USA

CE2 - COST EFFECTIVENESS OF ADDING CLOSTRIDIAL COLLAGENASE OINTMENT TO STANDARD OF CARE IN INDIVIDUALS WITH STAGE IV PRESSURE ULCERS

Carter M1, Gilligan A2, Waycaster CR3, Schaum K41Strategic Solutions Inc., Cody, WY, USA, 2Truvan Health Analytics, Ann Arbor, MI, USA, 3Smith & Nephew Inc., Fort Worth, TX, USA, 4Smith & Nephew Inc., Lake Worth, FL, USA

The presentation described the cost effectiveness of adding an enzymatic debridement agent (clostridial collagenase ointment) to the standard of care given to individuals with stage IV pressure ulcers; this was the first data of its kind, which also demonstrated that this agent increases the cost effectiveness very substantially.

MA2 - HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES

Agarwal P1, Bias T1, Sambamoorthi U21West Virginia University, Morgantown, WV, USA, 2West Virginia University, School of Pharmacy, Morgantown, WV, USA

Best Student Podium Research Presentations

SY4 - ECONOMIC EVALUATION OF AN AUTOMATED RETINAL IMAGE ANALYSIS IN AUSTRALIAN ABORIGINAL AND TORRES STRAIT ISLANDER POPULATIONS FOR DETECTION OF DIABETIC RETINOPATHY

Ballreich J1, Burnett A2, Frick K1, Ho A2, Arkapaw L2, Kleinert A2
1Johns Hopkins University, Baltimore, MD, USA, 2Brien Holden Vision Institute and Vision Cooperative Research Centre, Sydney, Australia

We evaluated the use of an automated retinal image analysis screening method for detection of diabetic retinopathy in the Indigenous Australian population, and our results demonstrated significant costs savings under a variety of technical assumptions.

BI2 - ESTIMATING THE COSTS OF SUPPORTING SAFETY-NET TRANSFORMATION INTO PATIENT-CENTERED MEDICAL HOMES IN POST-KATRINA NEW ORLEANS

Camponeschi GF1, Bridges JF2, Danoff SK1, Richardson B1
Shao H1, Shi L1, Diana M1, Brown L2, Mason K2, Cocran D2, Carruth A2, Schmidt L3
1Tulane University, New Orleans, LA, USA, 2Louisiana Public Health Institute, New Orleans, LA, USA, 3University of California at San Francisco, San Francisco, CA, USA

Our study further addressed the difficulty for a safety-net clinic to transform into a patient-centered medical home (PCMH) without external funding, and our results provided monetary inference for the future policy which intend to support PCMH transformation among safety-net clinics.

CO3 - COMPARATIVE EFFECTIVENESS OF PANITUMUMAB VERSUS CETUXIMAB IN PATIENTS WITH CHEMO-REFRACTORY WILD-TYPE KRAS METASTATIC COLORECTAL CANCER

Xu Y, Hay JW, Barzi A
University of Southern California, Los Angeles, CA, USA

It is a good case study which shows that specialty drugs with similar clinical efficacy may differ in other factors, such as administration schedule, toxicity and its treatment cost, quality of life, and thus providing overall advantage on top of clinical benefit.

Best New Investigator Podium Research Presentations

CN1 - THE POTENTIAL CLINICAL, RESOURCE USE, AND FISCAL IMPACTS OF LUNG-RADS TO INFORM LUNG CANCER SCREENING IN MEDICARE

Roth J1, Sullivan SD2, Ramsey S1, Goulart B1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA

Our simulation modeling study demonstrated that over a 3-year period for Medicare eligible patients, full adoption of Lung-RADS to manage lung cancer screening is expected to produce 0.5 to 1 million fewer false-positive screening results, 5,000 to 11,000 fewer invasive diagnostic follow-up procedures, and direct medical expenditure savings of $128 to $256 million. These findings suggest that nuanced lung cancer screening management systems can have important clinical, resource use, and fiscal impacts in addition to reducing physical and psychological harms from false-positive screening results.

CV2 - EFFECTIVENESS AND SAFETY OF REDUCED DOSE NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITHOUT SEVERE RENAL IMPAIRMENT

Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA
Mayo Clinic, Rochester, MN, USA

In routine clinical practice, one in eight patients with no renal indication for dose reduction received a reduced-dose novel oral anticoagulant (NOAC), which may be associated with reduced effectiveness in stroke prevention without any improvement in safety in patients treated with apixaban.

PR2 - GENERIC INJECTABLE SHORTAGES AND TRENDS IN AVERAGE SALES PRICE IN THE UNITED STATES

Hur P1, Ray D2, Vegesna A3, Obi EN2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Rutgers University, Piscataway, NJ, USA, 3Jefferson College of Population Health, Philadelphia, PA, USA

This study examined trends of Average Sales Price for Medicare Part B generic sterile injectables on shortage in order to assist pharmacy budget management.

 

ISPOR 2015 (20th Annual)

Best General Podium Presentations

PP2 - PATIENT PREFERENCES FOR FIRST-LINE MAINTENANCE TREATMENTS FOR OVARIAN CANCER

Mansfield CA1, Poulos C1, Hackshaw MD2, Pugh A1, Jobanputra MH2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Philadelphia, PA, USA

 

CP4 - GUIDANCE FOR THE CONDUCT AND REPORTING OF MODELING AND SIMULATION IN THE CONTEXT OF HEALTH TECHNOLOGY ASSESSMENT

Dahabreh I1, Balk E1, Wong JB2, Trikalinos TA1
1Brown University, Providence, RI, USA, 2Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

DB4 - DEVELOPMENT AND VALIDATION OF ALGORITHMS TO IDENTIFY STATIN INTOLERANCE IN A US ADMINISTRATIVE DATABASE

Foody JM1, Lamerato L2, Dalal M3, Sung JC3, Khan I3, Jhaveri M3, Koren A3Schulman KL4
1Harvard Medical School, Boston, MA, USA, 2Henry Ford Health System, Detroit, MI, USA, 3Sanofi US, Inc., Bridgewater, NJ, USA, 4Outcomes Research Solutions, Inc., Bolton, MA, US

Best Student Podium Research Presentations

HT2 - APPLICATION OF COST-EFFECTIVENESS LOGIC TO US MANAGED CARE DRUG FORMULARIES: LONG TERM OUTCOMES OF A VALUE-BASED FORMULARY

Yeung K1, Basu A2, Hansen RN1, Watkins J3, Sullivan SD2
1School of Pharmacy, University of Washington, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Premera Blue Cross, Mountlake Terrace, WA, USA

PP4 - MEASURING TREATMENT PREFERENCES OF PATIENTS DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS USING BEST-WORST SCALING

Camponeschi GF1, Bridges JF2, Danoff SK1, Richardson B1
1Johns Hopkins University, Baltimore, MD, USA, 2John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

CS1 - US BASED DRUG COST PARAMETER ESTIMATES USING NATIONAL AVERAGE DRUG ACQUISITION COST

Levy JF, Rosenberg MA, Vanness DJ
University of Wisconsin-Madison, Madison, WI, USA

Best New Investigator Podium Research Presentations

CV4 - OUTCOMES AND HEALTH RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AT AN ACADEMIC MEDICAL CENTER (AMC) IN THE UNITED STATES

Bress A1, King J1, Singhal M1, Brixner D1, Kielhorn A2, Patel H2, Maya J2, Biskupiak JE1, Munger M1
1University of Utah, Salt Lake City, UT, USA, 2Amgen, Thousand Oaks, CA, USA

CS2 - ECONOMIC MODELLING IN RANDOMIZED CONTROLLED TRIAL (RCT)-BASED ECONOMIC EVALUATIONS: EMPIRICAL EXAMPLES OF ITS EFFECT ON THE PRECISION OF ECONOMIC AND DECISION OUTCOMES

Nam J, Berry C, Henderson R, Briggs A
University of Glasgow, Glasgow, UK

CS3 - URE MODELS: ACCOUNTING FOR CURED PATIENTS IN ECONOMIC EVALUATIONS

Othus M1, Bansal A2, Koepl L1, Wagner S3, Ramsey S1 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Bristol-Myers Squibb, Washington Crossing, PA, USA

ISPOR 2014 (19th Annual)

Best General Podium Presentations

PP2 - PATIENT PREFERENCES FOR FIRST-LINE MAINTENANCE TREATMENTS FOR OVARIAN CANCER

Mansfield CA1, Poulos C1, Hackshaw MD2, Pugh A1, Jobanputra MH2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Philadelphia, PA, USA

 

CP4 - GUIDANCE FOR THE CONDUCT AND REPORTING OF MODELING AND SIMULATION IN THE CONTEXT OF HEALTH TECHNOLOGY ASSESSMENT

Dahabreh I1, Balk E1, Wong JB2, Trikalinos TA1
1Brown University, Providence, RI, USA, 2Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

DB4 - DEVELOPMENT AND VALIDATION OF ALGORITHMS TO IDENTIFY STATIN INTOLERANCE IN A US ADMINISTRATIVE DATABASE

Foody JM1, Lamerato L2, Dalal M3, Sung JC3, Khan I3, Jhaveri M3, Koren A3Schulman KL4
1Harvard Medical School, Boston, MA, USA, 2Henry Ford Health System, Detroit, MI, USA, 3Sanofi US, Inc., Bridgewater, NJ, USA, 4Outcomes Research Solutions, Inc., Bolton, MA, US

Best Student Podium Research Presentations

HT2 - APPLICATION OF COST-EFFECTIVENESS LOGIC TO US MANAGED CARE DRUG FORMULARIES: LONG TERM OUTCOMES OF A VALUE-BASED FORMULARY

Yeung K1, Basu A2, Hansen RN1, Watkins J3, Sullivan SD2
1School of Pharmacy, University of Washington, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Premera Blue Cross, Mountlake Terrace, WA, USA

PP4 - MEASURING TREATMENT PREFERENCES OF PATIENTS DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS USING BEST-WORST SCALING

Camponeschi GF1, Bridges JF2, Danoff SK1, Richardson B1
1Johns Hopkins University, Baltimore, MD, USA, 2John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

CS1 - US BASED DRUG COST PARAMETER ESTIMATES USING NATIONAL AVERAGE DRUG ACQUISITION COST

Levy JF, Rosenberg MA, Vanness DJ
University of Wisconsin-Madison, Madison, WI, USA

Best New Investigator Podium Research Presentations

CV4 - OUTCOMES AND HEALTH RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AT AN ACADEMIC MEDICAL CENTER (AMC) IN THE UNITED STATES

Bress A1, King J1, Singhal M1, Brixner D1, Kielhorn A2, Patel H2, Maya J2, Biskupiak JE1, Munger M1
1University of Utah, Salt Lake City, UT, USA, 2Amgen, Thousand Oaks, CA, USA

CS2 - ECONOMIC MODELLING IN RANDOMIZED CONTROLLED TRIAL (RCT)-BASED ECONOMIC EVALUATIONS: EMPIRICAL EXAMPLES OF ITS EFFECT ON THE PRECISION OF ECONOMIC AND DECISION OUTCOMES

Nam J, Berry C, Henderson R, Briggs A
University of Glasgow, Glasgow, UK

CS3 - URE MODELS: ACCOUNTING FOR CURED PATIENTS IN ECONOMIC EVALUATIONS

Othus M1, Bansal A2, Koepl L1, Wagner S3, Ramsey S1 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Bristol-Myers Squibb, Washington Crossing, PA, USA

ISPOR 2013 (18th Annual)

Best General Podium Presentations

CA1 - BREAST CANCER PATIENTS RECEIVING GUIDELINE-CONCORDANT ADJUVANT THERAPY REGIMENS HAVE BETTER ALL-CAUSE AND DISEASE-SPECIFIC SURVIVAL: NEW FINDINGS FROM RURAL GEORGIA

Lipscomb J1, Guy GP2, Gillespie T3, Goodman M1, Richardson LC2, Ward KC1
1Emory University, Rollins School of Public Health, Atlanta, GA, USA, 2Centers for Disease Control and Prevention, Atlanta, GA, USA, 3Emory University School of Medicine, Atlanta, GA, USA

 

CA3 - TREATMENT PATTERNS AFTER CASTRATION RESISTANT PROSTATE CANCER (CRPC) DIAGNOSIS: A EUROPEAN PHYSICIAN SURVEY

Pokras SM1, Zyczynski TM2, Lees M3, Jiao X1, Blanchette C1, Powers J4
1IMS Health, Alexandria, VA, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4University of Colorado, Denver, Aurora, CO, USA

 

SB2 - MEDICAL, DRUG, AND WORK-LOSS COSTS OF DIABETIC FOOT ULCERS

Rice JB1, Desai U1, Cummings AK1, Birnbaum HG1, Skornicki M2, Parsons N2
1Analysis Group, Inc., Boston, MA, USA, 2Organogenesis Inc., Canton, MA, USA

 

Best Student Podium Research Presentations

DU4 - THE ASSOCIATION OF BURN INJURIES AND PSEUDOEPHEDRINE SALES

Goodin AJ, Perin NR, Freeman PR, Talbert J, Wittmer D, Blumenschein K
University of Kentucky, Lexington, KY, USA

 

MD2 - SKELETAL-RELATED EVENTS AND MORTALITY AMONG SEER-MEDICARE PATIENTS WITH METASTATIC PROSTATE CANCER: THE IMPLICATIONS OF MEASUREMENT APPROACH

Onukwugha E1Yong C1, Mullins CD1, Seal B2, Hussain A3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 3University of Maryland School of Medicine, Baltimore, MD, USA

 

MD3 - ASSOCIATION BETWEEN INHALED ANTICHOLINERGICS USE AND ALL-CAUSE MORTALITY AMONG ELDERLY MEDICARE BENEFICIARIES WITH RESPIRATORY DISEASES

Ajmera MR1, Pan X1, Findley P2, Rust G3, Sambamoorthi U4
1West Virginia University, Morgantown, WV, USA, 2Rutgers University, New Brunswick, NJ, USA, 3Morehouse School of Medicine, Atlanta, GA, USA, 4West Virginia University School of Pharmacy, Morgantown, WV, USA

 

Best New Investigator Podium Research Presentations

HT1 - INTER-COUNTRY VARIABILITY IN COVERAGE DECISIONS FOR ORPHAN DRUGS: CRITERIA DRIVING HTA RECOMMENDATIONS IN SIX COUNTRIES

Nicod E, Kanavos P
London School of Economics and Political Science, London, UK

 

RM2 - USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS AND RISK OF DEMENTIA IN HEART FAILURE

Chitnis AS1, Johnson ML2, Aparasu RR2, Chen H2, Kunik ME3, Schulz PE4
1United BioSource Corporation, Lexington, MA, USA, 2University of Houston, Houston, TX, USA, 3Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC), Houston, TX, USA, 4The University of Texas Health Science Center at Houston, Houston, TX, US

 

RM3 - SULFONYLUREAS ARE ASSOCIATED WITH ELEVATED RISK OF HIP FRACTURES AMONG ELDERLY MEN AND WOMEN WITH TYPE-2 DIABETES

Rajpathak SN1, Fu C1, Engel SS1, Brodovicz KG1, Lapane K2
1Merck & Co, North Wales, PA, USA, 2University of Massachussets, Worcester, MA, USA

 

 

ISPOR Europe Conference Award Winners

ISPOR Europe 2017 (20th Annual)

Best General Podium Presentations

AD4: PREDICTIVE ANALYSIS FOR IDENTIFYING PATIENT CHARACTERISTICS ASSOCIATED WITH PRIMARY MEDICATION NONADHERENCE FOR LIPID LOWERING THERAPIES

Pallavi B. Rane
Amgen Inc., Thousand Oaks, CA, USA

SY1: PSORIASIS DRUGS IN EUROPE - MARKET ACCESS DECISIONS IN COMPARISON BASED ON THE PRISM ACCESS DATABASE

Lutz Vollmer
MArS- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany

AD1: EXPLORING FACTORS EXPLAINING TREATMENT ACCEPTANCE IN PATIENTS SUFFERING FROM A CHRONIC DISEASE

Elodie de Bock
Mapi, Patient Centered Outcomes, Lyon, France

Best Student Podium Research Presentations

IN4: COST-EFFECTIVENESS OF ADDITIONAL VACCINATION OF BOYS AGAINST HPV IN GERMANY

Oliver Damm
School of Public Health, Bielefeld University, Bielefeld, Germany

CV2: A FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF NOVEL BIOMARKER TESTING IN CARDIOVASCULAR DISEASE

Ciaran N. Kohli-Lynch
University of Glasgow, Glasgow, UK

IN2: COST-EFFECTIVENESS AND MODELING APPROACHES OF DIRECT-ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC LITERATURE REVIEW

László Szilberhorn
Eötvös Loránd University (ELTE), Budapest, Hungary

Best New Investigator Podium Research Presentations

AD3: FACTORS ASSOCIATED WITH AN ADHERENCE WITH ANTIEPILEPTIC DRUGS IN CHILDREN TREATED IN PEDIATRIC PRACTICES IN GERMANY

Silvia Dombrowski
QuintilesIMS, Frankfurt am Main, Germany

PP2: CHOICE OF INSTRUMENT IMPACTS HEALTHCARE DECISIONS: EFFECT OF SOURCE OF UTILITY DERIVED FROM THE SAME PATIENT POPULATION ON COST-EFFECTIVENESS

Necdet B. Gunsoy
GSK, Uxbridge, UK

PP1: MIMICKING REAL LIFE DECISION-MAKING IN HEALTH: ALLOWING RESPONDENTS TIME-TO-THINK IN A DISCRETE CHOICE EXPERIMENT

J Veldwijk
Erasmus University Rotterdam, Rotterdam, The Netherlands

ISPOR Europe 2016 (19th Annual)

Best General Podium Presentations

HT1-ALIGNED AND FLEXIBLE? A COMPARATIVE REVIEW OF SMC AND NICE DECISION-MAKING

Johnson H1, Spoors J2, Johnson J1
1Helen Johnson Consulting Ltd, Welwyn Garden City, UK, 2RJW & Partners, Royston, UK

AD3-MEDICATION ADHERENCE AND PERSISTANCE IN TYPE 2 DIABETES MELLITUS (T2DM): PATIENTS PERSPECTIVE IN THE SPANISH HEALTH CARE SYSTEM

Labrador Barba E1, Hernandez Mijares A2, Alonso Moreno FJ3, Rodriguez de Miguel M1, Orera Peña ML1, Aceituno Mata S4, Perez L4, Faus Dader MJ5
1Mylan, Barcelona, Spain, 2Dr. Peset Hospital, Valencia, Spain, 3Sillería Health Center, Toledo, Spain, 4Outcomes’10, Castellon, Spain, 5Faculty of Pharmacy, Granada, Spain

A patient-centered research about the factors and strategies which diabetes patients consider important for their treatment adherence. Our results could help health professionals to improve poor adherence management by the incorporation of patients’ opinions and preferences.

DB1-MORTALITY EXCESS DUE TO CLOSTRIDIUM DIFFICILE INFECTION - A NATIONAL DATABASE ANALYSIS

Bouee S1, Levy Bachelot L2, Ravonimbola H2, Longepierre L1, Godard C2, Gourmelen J3, Barbut F4

1CEMKA, Bourg La Reine, France, 2MSD France, Courbevoie, France, 3UMS 011 - Inserm - UVSQ, Villejuif, France, 4Laboratory for Clostridium Difficile, Paris, France

Best Student Podium Research Presentations

ND1-BURDEN AND WORK PRODUCTIVITY LOSS IMPAIRMENT FROM PROVIDING CARE TO ALZHEIMER'S DISEASE PATIENTS

Hu X1, Ritchie C2, Wood R3, Jones E3, Black CM4, Khandker RK4, Ambegaonkar BM4
1University of Southern California, Los Angeles, CA, USA, 2University of Edinburgh, Edinburgh, UK, 3Adelphi Real World, Bollington, UK, 4Merck & Co., Inc., Rahway, NJ, USA

PP1-NINE TESTS FOR ASSESING VALIDITY OF A DISCRETE-CHOICE EXPERIMENT

Janssen EM, Bridges JF
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

DB4-USE OF DATA-MINING TO PERFORM A REAL WORLD COST ANALYSIS OF HER2-POSITIVE BREAST CANCER IN IRAN

Ansaripour A1, Zendehdel K2, Tadayon N3, Sadeghi F4, Uyl-de Groot C5, Redekop WK6
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Tehran Medical Sciences and Medical Education University, Tehran, Iran, 3Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of), 4Tehran Medical Sciences and Medical education University, Tehran, Iran, 5National Health Care Institute, Diemen, The Netherlands, 6National University of Singapore, Singapore, Singapore

Best New Investigator Podium Research Presentations

HT6-CRITERIA DRIVING VALUES ASSESSMENTS IN MULTIPLE SCLEROSIS MEDICINES

Visintin E1, Kanavos P2
1London School of Economics and Political Sciences, London, UK, 2London School of Economics and Political Science, London, UK

EE2-IS IT REALLY COST-EFFECTIVE TO RISK-ASSESS ALL HOSPITALIZED PATIENTS FOR PRESSURE ULCERS EVERY NURSING-SHIFT?

Padula WV1, Onyekwere U1, Makic MB2, Wald HL2, Epstein Z3, Meltzer DO4
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2University of Colorado, Aurora, CO, USA, 3Pomona College, Claremont, CA, USA, 4University of Chicago, Chicago, IL, USA

PP3-PATIENTS' PREFERENCES FOR CHARACTERISTICS OF PERIODONTAL DISEASE AND ITS' TREATMENT: A DISCRETE CHOICE EXPERIMENT

Vennedey V1, Danner M1, Civello D1, Schwalm A2, Seidl A2, Hiligsmann M3, Stock S1
1University Hospital Cologne, Cologne, Germany, 2Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 3Maastricht University, Maastricht, The Netherlands

 

ISPOR Europe 2015 (18th Annual)

Best General Podium Presentations 

CA1 - ANALYSIS OF THE RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS WITHOUT PRIOR CHEMOTHERAPY

Traina S1, Li T1, Johnson K1, Ho KF2, Molina A3, Cella D4
1Janssen Research & Development, Raritan, NJ, USA, 2STAT-TU Inc., Toronto, ON, Canada, 3Janssen Research & Development, Menlo Park, CA, USA, 4Northwestern University Feinberg School of Medicine, Chicago, IL, USA

EA2 - ACCESS TO INNOVATIVE DRUGS IN PATIENTS WITH METASTATIC LUNG CANCER IN FRENCH PUBLIC HOSPITALS (THE TERRITOIRE STUDY)

Scherpereel A1, Fernandes J2, Cotté F3, Blein C4, Debieuvre D5, Durand-Zaleski I6, Gaudin A3, Ozan N3, Saitta B4, Souquet P7, Vainchtock A4, Westeel V8, Chouaïd C9
1CHU Lille, Lille, France, 2Oc Santé, Montpellier, France, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4HEVA, Lyon, France,5Mulhouse Hospital, Mulhouse, France, 6URC Eco, Paris, France, 7Hospices Civils de Lyon, Lyon, France, 8Besançon Hospital, Besançon, France, 9CHIC, Créteil, France

PR2 - PREDICTING POST-AMNOG REBATE OUTCOMES FOR ONCOLOGY DRUGS

Subramanian D, Lazaro V
Qlaar Pte. Ltd., Singapore, Singapore

 

Best Student Podium Research Presentations

PR1 - DETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS

Korchagina D1, Vataire A2, Toumi M3, Falissard B4, Aballéa S2
1University of Paris-Sud, Paris, France, 2Creativ-Ceutical, Paris, France, 3Aix-Marseille University, Marseille, France, 4Maison de Solenn, Paris, France

EA4 - ORPHAN DESIGNATIONS AND APPROVALS IN THE EU, UNITED STATES AND JAPAN

Korchagina D1, Tomita N2, Falissard B3, Toumi M4, Tavella F5
1University of Paris-Sud, Paris, France, 2National Institute of Public Health, Saitama, Japan, 3Maison de Solenn, Paris, France,4Aix-Marseille University, Marseille, France, 5Creativ-Ceutical, London, UK

RM8 - COMPARISON OF TIMED AUTOMATA WITH DISCRETE EVENT SIMULATION FOR MODELING PERSONALIZED TREATMENT DECISIONS: THE CASE OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Degeling K, Koffijberg H, Schivo S, Langerak R, IJzerman MJ
University of Twente, Enschede, The Netherlands

 

Best New Investigator Podium Research Presentations

VA3 - ECONOMIC EVALUATION OF CHILDREN VACCINATION FROM 2 TO 18 YEARS OF AGE WITH THE LIVE ATTENUATED INFLUENZA VACCINE COMPARED WITH THE EXISTING VACCINES IN THE PORTUGUESE SETTING

Ferreira J1, Trindade R1, Norte J1, Sackeyfio A2
1Astrazeneca Produtos Farmacêuticos Lda., Lisboa, Portugal, 2AstraZeneca Alderley House, Alderley Park, UK

MD4 - COST-EFFECTIVENESS OF 18F-FDG PET/CT FOR SCREENING DISTANT METASTASIS IN STAGE II/III BREAST CANCER PATIENTS OF THE UK, THE UNITED STATES AND THE NETHERLANDS

Miquel-Cases A1, Teixeira S1, Retèl V1, Steuten L2, Valdés Olmos R1, Rutgers E1, van Harten WH1
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Washington and Panaxea bv, Seattle, WA, USA

CA3 - THE BURDEN OF CANCER IN EMERGING ECONOMIES: PRODUCTIVITY LOSS AS AN ALTERNATIVE PERSPECTIVE

Pearce A1, Hanly P2, Sharp L3, Soerjomataram I4
1National Cancer Registry Ireland, Cork, Ireland, 2National College of Ireland, Dublin, Ireland, 3Newcastle University, Newcastle, UK, 4International Agency for Research on Cancer, Lyon, France

 

 

ISPOR Asia Pacific Conference Award Winners

ISPOR Asia Pacific 2018

 View the awardees here.

 

ISPOR Asia Pacific 2016 (7th Biennial)

 

CE1-CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF NOVEL ORAL ANTICOAGULANTS INCORPORATING REAL-WORLD ELDERLY PATIENTS WITH ATRIAL FIBRILLATION

Zhao YJ1, Lin L1, Zhou HJ1, Khoo AL1, Tan KT2, Chew AP3, Foo CG4, Oh CT5, Lim WS3, Lim BP1
1Pharmacy and Therapeutics Office, Group Corporate Development, National Healthcare Group, Singapore, Singapore, 2Department of Pharmacy, Tan Tock Seng Hospital, Singapore, Singapore, 3Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore, Singapore, 4Department of Cardiology, Tan Tock Seng Hospital, Singapore, Singapore, 5Department of Neurology, National Neuroscience Institute, Singapore, Singapore, Singapore

RM4-RELIABILITY AND VALIDITY OF THE HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) IN PATIENTS WITH SPONDYLOARTHRITIS

Kwan YH1, Yong ST2, Fong W2, Lui NL2, Malhotra R1, Thumboo J3, Ostbye T1
1Duke-NUS Medical School, Singapore, Singapore, 2Singapore General Hospital, Singapore, Singapore, 3Singhealth, Singapore, Singapore

RM3-COMPARISON OF CAREGIVER-RATED 3-LEVEL EUROQOL-5D (EQ-5D-3L) AND HEALTH UTILITIES INDEX MARK 3 (HUI3) IN PATIENTS WITH DEMENTIA IN SINGAPORE

Wang VW1, Kandiah N2, Lin X2, Wee HL1
1National University of Singapore, Singapore, Singapore, 2National Neuroscience Institute, Singapore, Singapore

HC4-DERIVATION AND EXTERNAL VALIDATION OF AN EARLY READMISSION RISK PREDICTION MODEL

Dorajoo SR1, See V1, Chan CT1, Tan ZY2, Koomanan N3, Ong TT4, Razak SM4, Yap CW1, Chan A1
1National University of Singapore, Singapore, Singapore, 2Khoo Teck Puat Hospital, Singapore, Singapore, 3Singapore General Hospital, Singapore, Singapore, 4Temasek Polytechnic, Singapore, Singapore

CU3-LIFE EXPECTANCY, QUALITY-ADJUSTED LIFE YEARS, AND TOTAL LIFETIME COSTS FOR AUSTRALIAN PEOPLE WITH MULTIPLE SCLEROSIS

Palmer AJ, Taylor B, Van der Mei I, Si L, Ahmad H
University of Tasmania, Hobart, Australia

IN3-EFFECTS OF HBSAG POSITIVITY DURING PREGNANCY ON ADVERSE MATERNAL OUTCOMES: A RETROSPECTIVE DATABASE ANALYSIS

Tan J1, Sun X2, Liu X3
1School of West China Public Health, Sichuan University, Chengdu, China, 2West China Hospital of Sichuan University, Chengdu, China, 3No. 2 West China Hospital of Sichuan University, Chengdu, China

 

ISPOR Asia Pacific 2014 (6th Biennial)

 

RR3 - AWARNESS AND PREVENTION OF CHRONIC DISEASES IN JAPAN

Gupta S1, Fukuda T2, Stankus AP1
1Kantar Health, Princeton, NJ, USA, 2National Institute of Public Health, Saitama, Japan

CV4 - DOES THE CURRENT RECOMMENDED TARGET LDL GOAL IMPROVE SURVIVAL FOR ACUTE CORONARY SYNDROME PATIENTS IN HONG KONG?

Lee VW, Chau R, Cheung H, Yu CM, Lam YY, Yan BP
The Chinese University of Hong Kong, Shatin, Hong Kong, China

IN2 - EFFECT OF VACCINATION AGE ON COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINATION AGAINST CERVICAL CANCER IN CHINA

Liu Y, Zhang Q, HU S, Zhao F
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

CV2 - MANAGEMENT OF ISCHAEMIC STROKE PATIENTS ENROLLED IN THE JAPAN STROKE DATABANK (JSD)

Murteira S1, Toumi M2, Dorey J3, Dabbous FM4, Kobayashi S5
1Lundbeck Japan KK, Tokoyo, Japan, 2University Claude Bernard Lyon 1, Lyon, France, 3Creativ-Ceutical USA, Chicago, IL, USA,4University of Illinois at Chicago, Chicago, IL, USA, 5Shimane University, Matsue-shi, Japan

DB2 - EFFICACY AND SAFETY OF HUMAN INSULIN VERSUS ANIMAL INSULIN AMONG PATIENTS WITH DIABETES IN CHINA: A META-ANALYSIS

Zhang HN1, Wang K2, Yang J2, Liu L2
1China Pharmaceutical University, Nanjing, China, 2Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China

CV3 - ECONOMIC EVALUATION OF CHANGE IN REIMBURSEMENT CRITERIA FOR LIPID-LOWERING DRUGS IN TAIWAN

Wu GH1, Wang Y2, Pwu R2
1Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, and Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei, Taiwan, 2Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, Taipei, Taiwan

 

ISPOR Asia Pacific 2012 (5th Biennial)

 

CN1 - STATINS AND THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATITIS B VIRUS INFECTION

Tsan Y1, Lee C1, Wang J2, Chen P1
1National Taiwan University, Taipei, Taiwan, 2National Cheng Kung University College of Medicine, Tainan, Taiwan

CN2 - HOW EARLY-STAGE NON-PERSISTENCE AND NON-ADHERENCE TO ADJUVANT HORMONAL THERAPY ASSOCIATED WITH POSTMENOPAUSAL BREAST CANCER MORTALITY IN TAIWAN

Hsieh KP1, Chen LC2, Chang CS1, Yang YH1
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2University of Nottingham, Nottingham, UK

CN4 - INPATIENT TREATMENT PATTERNS AND HEALTHCARE EXPENDITURES FOR HEPATOCELLULAR CARCINOMA AMONG POPULATION WITH URBAN BASIC HEALTH INSURANCE IN CHINA

Xiong X1, Li J1, Qiao Y2, Yu Z3, Zhang YJ4, Meng, W1, Zhang J1
1China Health Insurance Research Association, Beijing, China, 2Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China, 4Sino-American Shanghai Squibb Pharmaceuticals Ltd., Shanghai, China

CL3 - ANTICOAGULATION CONTROL OF A PHARMACIST MANAGED ANTICOAGULATION CLINIC IN A NATIONAL REFERRAL CENTRE IN MALAYSIA

Thanimalai S1, Shafie AA1, Ahmad Hassali MA1, Sinnadurai J2
1Universiti Sains Malaysia, Penang, Malaysia, 2Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekut, Malaysia

PR3 - UTILITY VALUES FOR CHEMOTHERAPY-RELATED ADVERSE EVENTS: A REVIEW OF THE LITERATURE

Shabaruddin FH1, Chen LC2, Elliott R2, Payne K3
1University of Malaya, Kuala Lumpur, Malaysia, 2University of Nottingham, Nottingham, UK, 3University of Manchester, Manchester, UK

PR4 - 5. THE EFFECT OF NEUROPATHIC PAIN ON HEALTH STATUS, WORK PRODUCTIVITY LOSS, AND HEALTH CARE RESOURCE USE IN JAPAN

DiBonaventura MD1, Fukuda T2, Stankus A3
1Kantar Health, New York, NY, USA, 2National Institute of Public Health, Saitama, Japan, 3Kantar Health, Princeton, NJ, USA

 

 

ISPOR Latin America Conference Award Winners

ISPOR Latin America 2017 (6th Biennial)

 

RM2: LACK OF STANDARDIZED METHODS FOR HANDLING MULTIPLES SOURCES FOR MODEL PARAMETERS: A SYSTEMATIC REVIEW

Rodrigo Antonini Ribeiro, IATS & HTAnalyze, Porto Alegre, Brazil

CE2: EVALUACIÓN DE LA COSTO-EFECTIVIDAD DE LA PRUEBA DE SECUENCIACIÓN COMPLETA DEL GEN CFTR POR TÉCNICA SANGER PARA PORTADORES ASINTOMÁTICOS EN POBLACIÓN COLOMBIANA DE PRIMER, SEGUNDO Y TERCER GRADO DE CONSANGUINIDAD CON HISTORIA FAMILIAR DE FIBROSIS QUÍSTICA. 

Ernesto Andrade, Universidad Nacional de Colombia, Bogota, Colombia

HT4: DEVELOPING AND PILOTING A VALUE FRAMEWORK AND A TOOL TO INFORM THE "EVIDENCE-TO-DECISION MAKING" PROCESS

Ernesto Andrade, Universidad Nacional de Colombia, Bogota, Colombia

HT4: DEVELOPING AND PILOTING A VALUE FRAMEWORK AND A TOOL TO INFORM THE "EVIDENCE-TO-DECISION MAKING" PROCESS

Andrea Alcaraz, Institute for Clinical Effectiveness and Health Policy (IECS), CABA, Argentina

RM4: DETERMINING THE BRAZILIAN POPULATION HEALTH STATUS: ESTIMATE OF HEALTH PRODUCTION FUNCTION

José Rodrigo Gobi, Universidade Estadual de Maringá, Maringá-PR, Brazil

CA4: COMPARISON OF THE ASSESSMENTS AND RECOMMENDATIONS ISSUED BY BRAZIL'S CONITEC AND CANADA'S CADTH FOR SELECT ONCOLOGY DRUGS

Jonas Montilva, Navigant Consulting, London, UK

CE1: COST-UTILITY ANALYSIS (CUA) OF TARGETED INTRAOPERATIVE RADIOTHERAPY ALONE (TARGIT-A) IN THE BRAZILIAN EARLY BREAST CANCER PATIENTS

Anil Vaidya, University of Alberta, Edmonton, AB, Canada

     

ISPOR Latin America 2015 (5th Biennial)

 

PP2 - AN EQ-5D-5L VALUE SET BASED ON URUGUAYAN POPULATION PREFERENCES: REPORT OF THE FIRST EXPERIENCE IN LATIN AMERICA

Augustovski F1, Rey-Ares L1, Irazola V1, Garay U1, Gianneo O2, Fernandez G2, Morales MR2, Gibbons L1, Ramos-Goñi JM3
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Fondo Nacional de Recursos, Montevideo, Uruguay, 3The EuroQol Group Foundation, Rotterdam, The Netherlands

RM3 - COMPARISON OF SOCIAL EQ-5D TIME TRADE-OFF VALUES IN CHILE 2008-2013: DO GEOGRAPHICAL DIFFERENCES REALLY MATTER? 

Zárate V1, Kind P2, Valenzuela P3
1Ministerio de Salud, Santiago, Chile, 2HSE University, St Petersburg, Russia, 3Datavoz, Santiago, Chile

PP4 - AN UNDEVELOPED PICTURE: THE AVAILABILITY OF UTILITY VALUATIONS IN LATIN AMERICA – HOW WILL THEY AFFECT QALYS?

Montgomery S1, Stewart G2, Kusel J1
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Consulting Ltd., Cambridge, UK

MD1 - EVALUACIÓN ECONÓMICA DEL CARDIO-DESFIBRILADOR IMPLANTABLE COMPARADO CON LA TERAPIA FARMACOLÓGICA OPTIMA PARA EL TRATAMIENTO DE LOS PACIENTES CON FALLA CARDIACA EN COLOMBIA

Atehortua SC1, Castro P1, Ceballos M2, Senior JM1, Saldarriaga C1, Giraldo N1
1Universidad de Antioquia, Medellín, Colombia, 2Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia

CV4 - ECONOMICS OF DIABETES MELLITUS: THEORY AND EVIDENCE FOR BRAZILIAN DATA IN 2008

Balbinotto G, Wiest R, Jacinto P
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

CE1 - COST-EFFECTIVENESS ANALYSIS FOR CERVICAL CANCER SCREENING USING HPV TESTS IN CHILE

Franco Figueira S1, Cachoeira CV1, Souza FH1, Kano BY1, Silva M2, Poulios N3
1Roche Diagnostics LATAM, São Paulo, Brazil, 2Roche Diagnostics Chile, Santiago, Chile, 3Roche Molecular Systems, Inc., Pleasanton, CA, USA

     

ISPOR Latin America 2013 (4th Biennial)

 

CV2 - ESTIMATION OF THE COST-EFFECTIVENESS OF APIXABAN IN NON-VALVULAR ATRIAL FIBRILLATION IN ARGENTINA 

Giorgi MA1, Caroli C2, Micone P3, Giglio ND4, Aiello EC5, Donato BMK6, Mould JF7, Radero G8, Casas M8
1CEMIC, Buenos Aires, Argentina, 2FLENI, Buenos Aires, Argentina, 3Universidad Austral, Buenos Aires, Argentina, 4Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina, 5Bristol-Myers Squibb, Buenos Aires, Argentina, 6Bristol-Myers Squibb, Wallingford, CT, USA, 7Pfizer, Inc., New York, NY, USA, 8Pfizer, Inc., Buenos Aires, Argentina

CV3 - PULSE PRESSURE AND STROKE RISK: DEVELOPMENT AND VALIDATION OF A STROKE RISK EQUATION

Ayyagari R1, Vekeman F2, Lefebvre P2, Ong SH3, Faust E1, Trahey A1, Machnicki G4, Duh MS1
1Analysis Group, Inc., Boston, MA, USA, 2Groupe d’analyse, Ltée, Montréal, QC, Canada, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Latin America & Canada, Buenos Aires, Argentina

BU4 - BUDGET IMPACT ANALYSIS OF ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

Vitale V, Asano E, Pereira ML
Janssen Cilag Farmaceutica, São Paulo, Brazil

FD3 - ¿PUEDE UN CAMBIO DEL 2003 EN EL REGLAMENTO EN EL CUADRO BÁSICO (CBM) EN MÉXICO IMPACTAR LA CANTIDAD DE ESTUDIOS CIENTÍFICOS PUBLICADOS DE EVALUACIÓN ECONÓMICA COMPLETOS DE MEDICAMENTOS (EECM) EN LOS ÚLTIMOS 10 AÑOS?

Márquez Cruz M1, Peralta Bácenas LA1, Ibarra Cázares AE1, Rodriguez Mendoza MM1, Pizarro Castellanos M2, Soto Molina H1
1Universidad Autónoma Metropolitana, México D.F., Mexico, 2Hospital Infantil Federico Gomez, México D.F., Mexico

TR1 - SELF-REPORTED HEALTH STATUS AND EQ-5D-3L VALUES OF THE ARGENTINE POPULATION: COMPARING 2005 VERSUS 2009 NATIONAL RISK FACTOR SURVEYS

Augustovski F, Rey Ares L, Gibbons L
Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

CV4 - ANÁLISIS DE COSTO-EFECTIVIDAD DEL USO DE ESTATINAS EN LA PREVENCION DE EVENTOS CARDIOVASCULARES EN COLOMBIA

Mould J1, Ordoñez J2, Gutierrez-Ardila MV3, Vargas Zea N3
1Pfizer, Inc., New York, NY, USA, 2Universidad CES, Medellin, Colombia, 3Pfizer S.A.S., Bogota, Colombia